Tamarand L. Darling

Tamarand L. Darling

Auto-generated profile, based on publicly available information

Tamarand L. Darling

Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Cell
Verified
Journal Article
Closed access
EWEmma S. Winkler
Emma S. Winkler
PGPavlo Gilchuk
Pavlo Gilchuk
JYJinsheng Yu
Jinsheng Yu
ABAdam Bailey
Adam Bailey
RCRita E. Chen
Rita E. Chen
MDMichael Diamond
Michael Diamond

1 July 2021 in Cell Reports
Verified
Journal Article
Open access
TBTraci L. Bricker
Traci L. Bricker
TDTamarand L. Darling
Tamarand L. Darling
AHAhmed O. Hassan
Ahmed O. Hassan
HHHouda H. Harastani
Houda H. Harastani
ASAllison Soung
Allison Soung
ABAdrianus C.M. Boon
Adrianus C.M. Boon
The development of an effective vaccine against SARS-CoV-2, the etiologic agent of COVID-19, is a global priority. Here, we compared the protective capacity of intranasal and intramuscular delivery of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein (ChAd-SARS-CoV-2-S) in Golden Syrian hamsters. While immunization with ChAd-SARS-CoV-2-S induced robust spike protein specific antibodies capable of neutralizing the virus, antibody levels in serum were higher in hamsters vaccinated by an intranasal compared to intramuscular route. Accordingly, against challenge with SARS-CoV-2, ChAd-SARS-CoV-2-S immunized hamsters were protected against less weight loss and had reduced viral infection in nasal swabs and lungs, and reduced pathology and inflammatory gene expression in the lungs, compared to ChAd-Control immunized hamsters. Intranasal immunization with ChAd-SARS-CoV-2-S provided superior protection against SARS-CoV-2 infection and inflammation in the upper respiratory tract. These findings support intranasal administration of the ChAd-SARS-CoV-2-S candidate vaccine to prevent SARS-CoV-2 infection, disease, and possibly transmission.

1 September 2021 in Immunity
Verified
Journal Article
Closed access
ASAaron J. Schmitz
Aaron J. Schmitz
JTJackson S. Turner
Jackson S. Turner
ZLZhuoming Liu
Zhuoming Liu
Julian Q ZhouJulian Q Zhou
Julian Q Zhou
IAIshmael D. Aziati
Ishmael D. Aziati
AEAli Ellebedy
Ali Ellebedy

2 August 2024 in Science Advances
Verified
Journal Article
Open access
TDTamarand L. Darling
Tamarand L. Darling
HHHouda H. Harastani
Houda H. Harastani
AJAstha Joshi
Astha Joshi
TBTraci L. Bricker
Traci L. Bricker
NSNadia Soudani
Nadia Soudani
ABAdrianus C. M. Boon
Adrianus C. M. Boon
COVID-19 vaccines have successfully reduced severe disease and death after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nonetheless, COVID-19 vaccines are variably effective in preventing transmission and symptomatic SARS-CoV-2 infection. Here, we evaluated the impact of mucosal or intramuscular vaccine immunization on airborne infection and transmission of SARS-CoV-2 in Syrian hamsters. Immunization of the primary contact hamsters with a mucosal chimpanzee adenoviral-vectored vaccine (ChAd-CoV-2-S), but not intramuscular messenger RNA (mRNA) vaccine, reduced infectious virus titers ~100-fold and 100,000-fold in the upper and lower respiratory tract of the primary contact hamster following SARS-CoV-2 exposure. This reduction in virus titer in the mucosal immunized contact animals was sufficient to eliminate subsequent transmission to vaccinated and unvaccinated hamsters. In contrast, sequential transmission occurred after systemic immunization with the mRNA vaccine. Thus, immunization with a mucosal COVID-19 vaccine protects against cycles of respiratory transmission of SARS-CoV-2 and can potentially limit the community spread of the virus.

26 October 2021 in mBio
Verified
Journal Article
Open access
WSWen Su
Wen Su
SSSin Fun Sia
Sin Fun Sia
ASAaron J. Schmitz
Aaron J. Schmitz
TBTraci L. Bricker
Traci L. Bricker
TSTyler N. Starr
Tyler N. Starr
ABAdrianus C. M. Boon
Adrianus C. M. Boon
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the main target for neutralizing antibodies. These antibodies can be elicited through immunization or passively transferred as therapeutics in the form of convalescent-phase sera or monoclonal antibodies (MAbs).

17 October 2025 in Science Immunology
Verified
Journal Article
Closed access
SMSameer Kumar Malladi
Sameer Kumar Malladi
DJDeepika Jaiswal
Deepika Jaiswal
BYBaoling Ying
Baoling Ying
WAWafaa B. Alsoussi
Wafaa B. Alsoussi
TDTamarand L. Darling
Tamarand L. Darling
AEAli Ellebedy
Ali Ellebedy
Germinal centers (GCs) are key sites for antibody diversification and affinity maturation. SARS-CoV-2 messenger RNA (mRNA) vaccines elicit robust GC B cell responses in humans, but how these responses influence the breadth of immunity against viral variants remains unclear. We analyzed GC B cell responses in nine healthy adults after mRNA booster immunization. We show that 77.8% of the B cell clones in the GC expressed representative monoclonal antibodies (mAbs) recognizing the spike protein, with 37.8% of these targeting the receptor binding domain (RBD). One RBD-targeting mAb, mAb-52, neutralized all tested SARS-CoV-2 strains, including the recent XEC variant. mAb-52 used the IGHV3-66 public clonotype, protected hamsters challenged against the EG.5.1 variant, and targeted the class I/II RBD epitope, closely mimicking the binding footprint of ACE2. Its broad reactivity was driven by extensive somatic hypermutation, underscoring the critical role of GC reactions in shaping cross-variant B cell immunity after SARS-CoV-2 booster vaccination.